Exelixis | EXEL - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Akebia Therapeutics USD 184.84M 18.4M 2025-12
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bayer EUR 5.9B 1.34B 2025-09
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Cytokinetics USD 122.52M 102.95M 2025-12
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 7.27B 2.52B 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Exelixis USD 482.49M 106.19M 2025-12
Genmab DKK 1.72B 46M 2025-12
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
MacroGenics USD 57.22M 22.91M 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Xencor USD 54.07M 25.78M 2025-12